NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
79.89 USD   +4.05%
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : NovoCure Limited, Q2 2021 Earnings Call, Jul 29, 2021

07/29/2021 | 08:00am EDT
Good day, ladies and gentlemen. Thank you for standing by. Welcome to the NovoCure Second Quarter 2021 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference may...


© S&P Capital IQ 2021
All news about NOVOCURE LIMITED
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -102x
Yield 2022 -
Capitalization 8 368 M 8 368 M -
EV / Sales 2022 15,5x
EV / Sales 2023 14,6x
Nbr of Employees 1 167
Free-Float 86,8%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 79,89 $
Average target price 94,25 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED6.41%8 368
SHOCKWAVE MEDICAL, INC.55.56%9 967
MASIMO CORPORATION-46.11%8 757
PENUMBRA, INC.-39.77%6 557
GETINGE AB-45.18%6 026
IRAY TECHNOLOGY COMPANY LIMITED2.13%5 476